NCT05132790

Breast Cancer Study of Stereotactic Body Radiation Therapy (SBRT) Combined Neoadjuvant Treatment

Study to Evaluate the Efficacy and Safety of Stereotactic Body Radiation Therapy (SBRT) Combined Neoadjuvant Treatment for Patients With Triple-negative and Hormone Receptor-positive, HER2-negative Breast Cancer

• Status: Active Not Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 24 (estimated)
• Sponsor: Shengjing Hospital · Academic / Other
• Sex: Female
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The study is being conducted to evaluate the efficacy and safety of stereotactic body radiation therapy (SBRT) combined neoadjuvant treatment for patients with triple-negative and hormone receptor-positive, HER2-negative breast cancer

Conditions

• Breast Cancer

Interventions

Type	Name	Description
DRUG	SHR-1316 at a dose 20mg/kg q3w	Combination of SBRT and SHR1316, followed by SHR1316 plus nab-paclitaxel and carboplatin or cisplatin
DRUG	SHR6390 at a dose of 150mg orally, daily	SHR6390 plus exemestane with/without ovarian function suppression/ablation (OFS) after SBRT
RADIATION	SBRT	radiation therapy for breast cance before surgery.

Timeline

• Start date: 2023-09-25
• Primary completion: 2024-12-31
• Completion: 2028-12-31
• First posted: 2021-11-24
• Last updated: 2024-01-03

Locations

1 site across 1 country: China